After initially cheering the deal, the stock market gave its thumbs-down to Mankind acquiring BSV at the premium valuations of eight times its FY24 revenues and 23 times its estimated ebitda of FY25. The Mankind stock opened 4.5 per cent higher on Friday but closed 3.6 per cent lower. Worries over funding of expensive deal and taking of debt for a debt-free company dragged down the positive sentiment.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/KeCSBsl
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment